

All MCOs: Change in Preferred Drug List Status for Hypoglycemics, Insulin and Related Drug Class Effective July 27, 2026

Background:

Due to high product demand, Sanofi is currently experiencing shipping delays with Lantus Solostar resulting in product backorder. In response, the Texas Health and Human Services Commission temporarily removed the non-preferred status from certain insulin products on the preferred drug list (PDL).

Key Details:

HHSC temporarily removed the non-preferred status for the following drugs in the table below, effective July 27, 2026.

Hypoglycemics, Insulin and Related

NDC	Drug Name
00002771501	BASAGLAR 100 UNIT/ML KWIKPEN
00002771559	BASAGLAR 100 UNIT/ML KWIKPEN

These changes allow providers to prescribe certain insulin products without the requirement of a PDL prior authorization and continue access to necessary medication for members.

MCOs should be in compliance with this status removal as of July 29, 2026.

Contact:

Vdp-formulary@hhs.state.tx.us
